drugset / Trial / NCT00583947

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

NCT00583947

Phase 2 Completed 53 enrolled Sumitomo Pharma America, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

To determine the safety and tolerability of Arformoterol Tartrate in children with asthma

Timeline

Start
2008-01
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Arformoterol Small molecule 7.5 ug Inhaled
Subject Arformoterol Small molecule 15 ug Inhaled
Subject Levalbuterol Other / unclassified 0.63 mg Inhaled

Indications